Leadership

Konstantinos Alataris, PhD

President and Chief Executive Officer

Dr. Alataris has served as our President and Chief Operating Officer since September 2015 and became our Chief Executive Officer in January 2016. Dr. Alataris was the Founder and Chief Executive Officer of Nevro Corp. (NYSE:NVRO), a company that developed an innovative, evidence-based neuromodulation platform for the treatment of chronic pain. Under Dr. Alataris’ leadership, Nevro advanced its product from concept to clinical development and to successful international commercialization. Dr. Alataris served as Head of Digital Healthcare Strategy at mc10inc, a wearable sensor company, and as the Executive Chairman of the Board of Directors at IRRAS AB, an emerging company developing devices for fluid management and drug delivery in CNS applications. Prior to founding Nevro Corp, he was Vice President at Bay City Capital, a healthcare focused venture capital firm based in San Francisco. He holds Master’s degrees in Electrical Engineering and Business and a Ph.D. in Biomedical Engineering with emphasis in Neuroscience from the University of Southern California.

Donald Kellerman, PharmD

VP, Clinical Development and Medical Affairs

Dr. Kellerman has served as our Vice President of Clinical Operations since July 2015. Prior to joining Zosano, Dr. Kellerman served as Senior Vice President of Clinical Development & Regulatory Affairs at Tonix Pharmaceuticals. Previously, Dr. Kellerman served as Senior Vice President of Clinical Development & Medical Affairs at MAP Pharmaceuticals, Inc. (acquired by Allergan, Inc.) for five years. Dr. Kellerman also held the position of Senior Vice President of Development at Inspire Pharmaceuticals, Inc. for nine years, where he was responsible for all aspects of drug development, including clinical research, regulatory affairs, project management and biostatistics. He also led groups responsible for running several clinical programs in the respiratory, ophthalmology and cardiovascular areas. In addition, Dr. Kellerman has served in various clinical and project leadership positions at Glaxo Wellcome, Sepracor, Inc., and E.R. Squibb and Sons, Inc. He has more than 25 years of experience in the development of prescription pharmaceuticals and has lead- or co-authored more than 80 publications. Dr. Kellerman holds Doctor of Pharmacy and Bachelor of Science degrees from the College of Pharmacy at the University of Minnesota.

Hayley Lewis, RAC

VP, Regulatory Affairs & Quality

Hayley Lewis has served as our Vice President of Regulatory Affairs and Quality since October 2015. Prior to joining Zosano, she was Vice President of Regulatory Affairs and Quality at Carbylan Therapeutics. While at Carbylan, Ms. Lewis was part of the executive team that took the company public in April of 2015, as well as being responsible for all regulatory and quality activities, both internally and for external development programs for the company. From 2003 to 2014, Ms. Lewis held positions of increasing responsibility, most recently the Senior Director of Regulatory Affairs at Depomed, Inc. During her tenure, she led the company in the approvals of three NDAs, Proquin®, Glumetza®, and Gralise®, as well as approvals of several supplemental NDAs for Gralise®, Cambia®, Zipsor® and Lazanda®, including a line extension for Glumetza®, CMC, and labeling changes for the neurology and pain product lines for Depomed’s portfolio. Ms. Lewis received a B.S. in Pharmaceutical Sciences from the University of Greenwich, and completed the Executive Program for Women Leaders at the Stanford Graduate School of Business.

Eric Scharin

VP, Operations & Engineering

Eric Scharin has served as our Vice President of Operations & Engineering since April, 2015. He has played a key role in the approval of five commercial pharmaceutical products, most recently Sumavel® DosePro® and Zohydro® ER in his role as Sr. Director of Engineering and Product Industrialization at Zogenix from 2007 to 2015. Prior to Zogenix, Mr. Scharin served as Director of Manufacturing at Tercica from 2003 to 2007, where he led the CM&C team which developed the successful MAA for Increlex (IGF-1). Mr. Scharin has also served in manufacturing, validation, process development, and engineering roles at Sensus Drug Development, Covance Biotechnology Services, and Biogen. Mr. Scharin received an M.S.C.E.P. degree from the Massachusetts Institute of Technology and a B.S. in Chemical Engineering from the California Institute of Technology.

Winnie Tso, CMA, CFM, CPA

Chief Financial Officer

Winnie Tso has served as our Chief Financial Officer since April 2014. From January 2014 to April 2014, Ms. Tso served as a consultant to us. Prior to joining us in January 2014, Ms. Tso served as Vice President, Finance and Corporate Controller of SciClone Pharmaceuticals, a publicly-traded specialty biopharmaceutical company, in 2013. Prior to that, Ms. Tso served in various Vice President and Principal Accounting Officer positions from 2009 to 2013, including at Velti plc where Ms. Tso helped lead Velti’s U.S. public offering raising in excess of $150 million in equity financing. Prior to Velti, Ms. Tso held senior finance positions at several publicly-traded biopharmaceutical companies, including ARYx Therapeutics, Titan Pharmaceuticals and Genelabs Technologies, where she was responsible for building the finance and accounting infrastructures and implementing systems of internal controls. Ms. Tso is a Certified Management Accountant, a Certified Financial Manager, a Certified Public Accountant licensed in the State of California and a member of the American Institute of Certified Public Accountants. Ms. Tso received her B.S. degree in Business Administration from the Haas School of Business at the University of California, Berkeley.

Peter Daddona, PhD

Scientific Advisor,
Former Chief Scientific Officer and Executive Vice President, Research & Development

Peter E. Daddona has served as the company’s scientific advisor since January 1, 2016 and prior to that he was Chief Scientific Officer and Executive Vice President, Research and Development since 2006, and as a member of our board of directors since the inception of Zosano Pharma Corporation (then named ZP Holdings, Inc.) in January 2012. Dr. Daddona has also served as Chief Scientific Officer of Zosano Pharma since July 31, 2006. Dr. Daddona founded Zosano Pharma in 2006 as a spin-off of Johnson & Johnson, prior to which he served as Vice President, Scientific Leader and Board member of The Macroflux(r) Internal Venture at Johnson & Johnson. Previously, Dr. Daddona was Vice President of Macroflux(r) Technology Development and Biological Sciences and served on the Strategic Product Portfolio Review Committee at ALZA Corporation in Mountain View, California, and held an appointment as Consulting Associate Professor of Dermatology at Stanford University. Before joining ALZA, Dr. Daddona served as Vice President, Immunobiology Research at Centocor, where he focused on preclinical development of therapeutic monoclonal antibodies. Prior to joining Centocor, Dr. Daddona served as Associate Professor of Biological Chemistry and Internal Medicine at the University of Michigan. Dr. Daddona earned his Ph.D. from the University of Connecticut and completed post-doctoral training at Duke University.